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Summary The aim of this study was to determine the proliferative activity within the epithelial cells of the
normal human breast in 122 patients (6 reduction mammoplasties and 116 fibroadenoma excisions) in relation
to age and the phase of the menstrual cycle. Thirty three of the patients were on oral contraceptives and 33
were parous.
Thin tissue slices were incubated with tritiated thymidine and processed for autoradiography. Other samples
were fixed directly and prepared for histology. The labelling, mitotic and apoptotic indices (LI, MI and Al)
were determined and all illustrated considerable variability. The labelling indices are significantly (P<0.05)
influenced by both patient age and stage during the menstrual cycle and ranged from 0-11.5%. Maximum LI
values were obtained on the 20.8th day of the cycle. A square root transformation of the data was used to
reduce the skewness of the data to a more normal distribution. The square root of the LI declined by 0.22 per
decade. The mitotic data showed similar significant (P<0.05) correlations against age and day of cycle with a
peak on the 21.5th day of the cycle, a decline by 0.072 per decade and a range from 0-0.6%. The data for
apoptotic cells were less clearly influenced by the stage of the menstrual cycle but showed a significant
(P<0.5) decline with age. The Al in parous patients was significantly higher than that in non-parous patients.
There was no significant effect of oral contraceptives on any of the parameters measured when age and stage
of cycle were taken into account. The considerable variability in the data could not be fully accounted for by
either technical factors, the age of the patients, or the day of the cycle.
We conclude that proliferation is negatively related to age and is influenced by the menstrual cycle but that
additional as yet unknown factors must account for a large part of the variability seen in the data.
Events which occur early in reproductive life, such as
exposure to ionising radiation or an early menarche, are
known to be related to the subsequent development of
malignant neoplasms of the breast (Land et al., 1980,
MacMahon et al., 1973). The breast may be susceptable
during this period because of a high rate of cellular prolifer-
ation and because carcinogenic agents may act preferentially
upon proliferating tissues (Russo et al., 1982, 1987). How-
ever there are few data concerning the association between
age and proliferative activity of the normal human breast
(Anderson et al., 1982, Meyer, 1977; Russo et al., 1987) and
one aim of this study was to investigate this relationship
further.
Oestrogen is a major growth promoting hormone of the
breast: under some circumstances progesterone acts as an
antioestrogen and appears to inhibit proliferation (Mauvais-
Jarvis et al., 1986). On the basis of these observations
Korenman (1980) proposed that the risk of breast cancer
was related to a defective luteal phase with low or absent
progesterone secretion. Women with anovular cycles would
therefore be at high risk because of the unopposed action of
oestrogen. In order to account for the increased risk asso-
ciated with an early menarche he proposed that early cycles
were likely to be anovular.
Ifprogesterone was acting as an antioestrogen the prolifer-
ation of mammary epithelium during the luteal phase of the
cycle would be expected to be lower than in the follicular
phase. A study by Vogel et al. (1981) reported, without
quantitative details, that mitotic activity was indeed hig-hest
during the follicular phase; however other reports, on relati-
vely small numbers of patients, suggest that proliferative
activity is maximal during the luteal phase (Meyer, 1977;
Masters et al., 1977; Ferguson & Anderson, 1981a; Longacre
& Bartow, 1986; Going et al., 1988). A second aim of this
study was to determine the proliferative activity of the
normal human breast in relation to the day of the menstrual
cycle in order to resolve these conflicting data.
One feature of all studies on human breast is the consider-
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able variabiliy from sample to sample. The full explanation
for this variability remains unclear but its existence indicates
that much data must be accumulated by many groups before
a complete understanding of the proliferative behaviour of
the breast is achieved.
In an attempt to study as normal tissue as possible we
have used biopsy material removed either away from the site
of a fibroadenoma or from reduction mammoplasties. Here
we present data on the labelling index, mitotic index and
apoptotic index of the normal breast and show that these
indices of proliferation decline with age and are higher
during the second half of the menstrual cycle.
Materials and methods
Patient selection
Patients attending the breast clinic at the University Hospital
of South Manchester were selected if, clinically, they had
solitary benign lesions or if they were undergoing reduction
mammoplasty. Each patient was interviewed on the day
before, or the day of, operation. The purpose and nature of
the research was explained and verbal consent obtained.
Details of the history and clinical features for each patient
were recorded. These included parity, stage of menstrual
cycle, age and whether or not oral contraceptives had been
used recently or at any time in the past.
Patients were excluded from the study if they had men-
strual irregularities or if the solitary benign lesion turned out
to be a manifestation of a more serious breast condition.
Altogether 122 patients were involved, 33 of whom had been
taking oral contraceptives and 33 were parous. Mitotic
indices and apoptotic indices were obtained on 113 and
tritiated thymidine labelling studies were conducted on 101
biopsies.
Tissue samples
Apart from the discreet solitary lesion the patients had
otherwise palpably normal beasts. At surgery only grossly
normal tissue was sampled. This was taken at a distance of
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at least 1 cm from the site of a fibroadenoma in 114, from
the axillary tail during biopsies of lymph modes in 2 and
during reduction mammoplasty in 6 patients.
Fresh tissue taken at the time of surgery was sliced into
1 mm thick pieces approximately 1 cm2 in area. Separate
pieces of tissue were immediately placed in Carnoy's fixative
for at least 30mins, for routine histological procedures and
for the determination of mitotic and cell death counts. These
sections were stained with Haematoxylin and eosin (H & E).
The 1 mm thick strips were placed in Hank's balanced salt
solution at 37°C containing 37kBqml-' (1 pCiml-') tri-
tiated thymidine (3HTdR) (specific activity 185GBqmmol-'
(5Cimmol- 1) Radiochemical Centre, Amersham, UK) for
1 h. The tissue was then fixed in Carnoy's fixative and
sectioned for autoradiography.
Autoradiograph preparation
The slides were dipped in Ilford K5 emulsion diluted 1:1
with distilled water. The slides were exposed for 6-7 days at
about 4°C and developed in D19 and stained with haema-
toxylin and eosin (H & E).
Scoring
(a) Epithelial cells per lobule Using the H & E preparations
the number of cross sections of terminal ductules per breast
lobule cross section was determined in 74 samples. The
number of epithelial cells per cross section of a terminal
ductule was also determined. Between about 100 and 2,500
epithelial cells were counted from each patient, the number
being determined by the size of the biopsy and the histology.
The product of the number of ductules and the number of
epithelial cells per ductule gave the number of epithelial cells
per breast lobule cross section.
(b) Labelled cells Labelled cells were identified if 3 or more
grains overlay the nucleus. For some of the earlier samples
the threshold was set at 5 grains per nucleus. In most cases,
the grain density was greatly in excess of this (Figure 1). A
minimum of 1,000 epithelial cells were scored. A slide was
only scored if it clearly contained labelled cells and in most
cases the scoring was restricted to the edge of the section in
case the 3HTdR failed to penetrate the tissue adequately.
This was a precaution that was adopted in the absence of
any firm evidence of 3HTdR penetration problems. Exclusive
peripheral labelling on a section was seen only occasionally.
(c) Mitotic cells Mitosis was identified by the loss of the
nuclear membrane and the condensation of the nuclear
chromatin. It included all stages from late prophase to late
anaphase. A minimum of 1,000 epithelial cells were counted
per patient.
(d) Cell death (Apoptosis) Dying cells were identified by the
condensation of their chromatin, initially at the margins
of the nucleus, a condensation of the cytoplasm and the
appearance of a characteristic halo around the cell.
The dying cells break up into small fragments which may
be phagocytosed by neighbouring epithelial cells or macro-
phages. These fragments are often clustered together and can
be counted as a single dying cell. An ultrastructural descrip-
tion of cell death in the breast has been described as
apoptosis (Ferguson & Anderson, 1981b). A minimum of
1,000 epithelial cells were counted per sample.
Labelled cells, mitotic figures and dead or dying cells
(apoptosis) were each expressed as an index of the total
number of epithelial cells.
Statistical analysis
(a) Methods A standard hierarchical multiple linear regres-
sion technique was used. As age and stage of menstrual cycle
were the dominant effects, terms describing these were
entered into the regression equation first, and terms for the
other independent variables only added if they were signifi-
cant. A significance level of 0.05 was used throughout.
The strong correlations between patient age, pill usage and
parity make it essential that allowance for age is made
before testing for effects due to the pill or parity.
(b) Transformation of the dependent variables The depen-
dent variables (proliferation indices and cell count indices)
were significantly positively skewed. A more normal distribu-
tion was obtained by applying a square root transformation
to the proliferative indices and a logarithmic transformation
to the cell count indices. A logarithmic transform was
considered for the proliferative indices, but this produced
significantly negatively skewed distributions, as well as intro-
ducing a degree of arbitrariness in the offset added to allow
for zero values in the data. Previous workers used logarith-
mic transformations (Meyer, 1977; Ferguson & Anderson,
1981a; Anderson et al., 1982; Going et al., 1988).
These transforms are purely empirical in nature, being
introduced to improve the validity of the statistical analysis.
They have no biological significance.
(c) Treatment of the menstrual cycle effects The cycle
lengths reported by the patients varied. The data were
therefore fitted to a day of cycle normalised to a standard
cycle length of 28 days.
The simplest mathematical function describing such perio-
dic behaviour is the single sinusoid.
A sin(27rD/L)+Bcos(27rD/L) (1)
where D is the day of cycle, L the cycle length and A and B
constants. This is the first term in a Fourier series describing
in full the periodic function, however there are insufficient
data to merit going beyond this first term. Terms such as (1)
were included in the regression equation, and the constants
A and B fitted.
As alternatives, the data were fitted using categorical
variables describing either the week of the cycle or the cycle
half (i.e. 1st half or 2nd half).
These alternatives avoid any assumptions about the func-
tional form of the periodic behaviour.
(d) Treatment of age effects Variables consisting of either
the chronological age in years, or the estimated number of
cycles since menarche were added to the regression equation.
(e) Other effects Other variables considered as candidates
for the regression models were categorical variables for on/
off the pill and parous/non-parous, and a number of interac-
tion terms including those between age and cycle, pill and
cycle and age and pill.
Figure 1 Autoradiographs of human breast tissue showing three
heavily labelled (large arrows) and one weakly labelled (small
arrow) cell.PROLIFERATION IN NORMAL HUMAN BREAST 165
Results
The mean age of the 122 patients was 25.8 +7.8 (s.d.) years
with a range of 14 to 48 years. The average length of their
menstrual cycles was 27.7+1.76 days with a range of 21 to
35 days (Table I).
The range of values for the total number of epithelial cells
per breast lobule was 32 to 285 based on 74 samples. The
number of cells per lobule was unrelated to the age of the
patient or the day of the menstrual cycle (Figure 2), or to
any other of the parameters tested (see Materials and
methods).
The LI was measured in 101 samples and related signifi-
cantly to both age of the patient and to the phase of the
menstrual cycle in which the biopsy was taken. The change
in LI during the menstrual cycle was cyclic with a peak value
on 20.8 days and a minimum value at 6.8 days (Figure 3a).
Because the LI also changed with age the values were
normalised to age 25 and the predicted best fit curve is
shown as a solid line in Figure 3a; the predicted best fit
curve for women aged 15 is shown as the upper dashed line
and for women aged 35 as the lower dashed line. No
significant effect of contraceptive pill or of parity on the LI
was observed. The square root of the LI declined signifi-
cantly with age by 0.22+0.8% per decade (Figure 3b).
Thus, for example, at age 25 the LI declines by 0.7% per
decade, that is by 44% of the fitted mean value (LI= 1.54%)
over the whole menstrual cycle at that age per decade. The
estimated effect of the menstrual cycle is illustrated by the
two lines in Figure 3b which represent the fitted regression
lines for patients at the 7th and 21st days of the cycle.
The regression on age and the cycle effects only account
for about 25% of the variability in the LI data. After taking
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these into account we estimate a standard deviation of +0.59
on the square root of each LI value. Technical error was
estimated by measuring the LI in six subsamples from the
same patient; the standard deviation for these values was
+0.15, which is significantly smaller (P<0.003) than 0.59.
This was confirmed in a second identical experiment.
The MI was meaasured in 113 samples and was also
significantly influenced by age and the day of the menstrual
cycle (Figure 4). The square root of the MI declined by
0.072+0.027% per decade. Thus at age 25 the MI declines
by 0.05% per decade, that is by 14% of the fitted mean
value (MI=0.35%) at that age.
The MI values are at their highest on day 21.5 and lowest
on day 7.5 of the cycle. No significant effect of the cycle on
the apoptotic index (measured in 113 samples) could be
detected but there was a significant decline with age
(Figure 5). The fitted square root of the AI of parous
patients (n=30) was 0.16+0.07 greater than that of non-
parous patients (n=83, P=0.03). The fitted variables in the
regression curves for both the square root of the MI and Al
account only for - 10% of the variation in the data.
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Figure 2 The total number of epithelial cells per lobule cross
section plotted against day of cycle. The total number of
epithelial cells is the product of the mean number of epithelial
cells per ductule cross section and the number of ductule cross
sections per lobule section * <25 years on the pill (+OCP),
A < 25 off the pill (- OCP), El _25 on the pill, A _25 off the
pill.
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Figure 3 Labelling index (LI) data. a. versus day of cycle. b
versus age. Symbols as for Figure 2 for a. For b 0 first half of
the cycle on the pill, A first half of the cycle off the pill, 0
second half of the cycle on the pill, A second half of the cycle off
the pill.
Table I Summary of results
Number
Mean S.D. Median Minimum Maximum of samplesa
Age (years) 25.8 7.8 24.0 14 48 122
Length of cycle (days) 27.7 1.76 27.9 21 35 114
LI (%) 2.65 2.20 2.20 0 11.5 101
MI (N) 0.16 0.15 0.11 0 0.59 113
Al (%) 0.34 0.33 0.27 0 1.60 113
Cross sections of ductules per lobule 7.24 3.15 6.55 3.70 25.2 74
Epithelial cell per duct cross section 11.8 2.6 11.5 6.6 19.3 74
Epithelial cells per lobule 84.1 37.4 75.0 31.8 284.8 74
a122 cases in total; different quantities of material and histological difficulties account for some of the variation in
sample size. Only 74 cases were analyzed for the number of ductule cross sections and the number of epithelial cells.
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Figure 4 Mitotic index (MI) data. a versus day of cycle. b v
age. Symbols as for Figure 2 for a and as for Figure 3b I
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-0.04 Figure 6 Summary of the labelling indices for human breast.
Upper series young (<25y) and old (>25y) patients at weekly
intervals throughout the menstrual cycle. Lower series the first
and second halves of the cycle compared for different aged
patients. Standard errors are shown. The total number of patients
analysed here (numbers within the bars) is less than shown in
Table I because the menstrual cycle data was inadequate for
some patients.
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Figure 5 Apoptotic index (Al) data. Symbols as for Figures 2
and 3. a versus day of cycle. b versus age.
The data as a whole can be summarized by the values
shown in Table I and the labelling index data, which show
the effects most dramatically, by the bar diagrams in Figure
6 which shows the changes through the menstrual cycle and
the influence of age. Both the increase in LI towards the end
of the cycle and the decline in LI with age can be seen.
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Figure 7 A comparison of patients on or off oral contracep-
tives. Standard error limits are shown. The number of patients is
shown in each bar.
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The lack of effect of oral contraceptive use upon the LI,
MI and Al during the menstrual cycle is shown in Figure 7.
These conclusions from the regression analyses are
unchanged if one uses half cycles or weeks of the cycle, or if
the estimated number of cycles since menarche are used
instead of chronological age. The latter alternative does give
a slightly better fit to the data, but not significantly so.
Discussion
Our data show that the proliferative activity of intralobular
epithelium of normal human breast shows considerable
variability, declines with age and is maximal in the second
half of the menstrual cycle. The variability is a feature
common to most studies involving many patients. Age and
day of cycle contribute only 10 to 25% to the variation seen
in our data. Technical errors when preparing and scoring
samples contribute further but our data suggest this is
insufficient to explain all of the remaining variability; other,
as yet unknown, biological factors presumably account for
the remainder of the variation. It would be hoped that by
accumulating many data sets, some or all may eventually be
pooled and hence the effects of factors such as parity, oral
contraceptives, laterality and site within the breast could be
better assessed.
A comparison of our data with other published reports is
shown in Table II. All studies have utilised histologically
normal tissue for the determination of proliferative indices;
this was either tissue taken away from the site of 'benign'
lesions, away from the site of carcinomas or from reduction
mammoplasties. Because fibrocystic disease can often affect
the breast diffusely we, and one other group (Ferguson &
Anderson, 1981a), chose mainly to use histologically normal
tissue away from the site of fibroadenomas since these
lesions are usually well circumscribed in mainly otherwise
normal breasts. The LI data described here tend as a
group to be slightly higher than the data of Flaxman and
Lasfargues (1973), Meyer (1977), Masters et al. (1977) and
Russo et al. (1987).
The mean apoptotic index is also slightly higher than that
presented by Ferguson & Anderson (1981a). However, the
range of LI and Al values is similar. The reasons for these
differences are not clear but could be related to differences in
technique or of patient populations. We could see little
evidence of the dampening effect of age on menstrual cycle
changes in Al (Figure 5) that were reported by Anderson et
al. (1982). However, our Al data were not significantly
influenced by the menstrual cycle, i.e., were already very
dampened (see Figure 5).
The validity of short term in vitro labelling studies can be
questioned. The main area of doubt is whether or not
3HTdR effectively penetrates to all levels within the 1 mm
thick slice of tissue. In order to partially overcome this
potential problem previous workers have either employed
increased levels of oxygenation or a complex process of
lobular dissection, neither of which we believe is necessary.
This is borne out by the fact that our LI values on the whole
are higher than previously published values and that labell-
Table II Summary of published human breast cell kinetics
Auto-
No. of Reasons for Age radiography MI% AI%
patients surgery range technique LI% mean (range) (range) (range) Comments Ref.
6 Normal ducts near 2pCiml 1 3.4 (0.1-0.3) (Flaxman &
nipple in patient 4h Lasfargues
with carcinoma 1973)
49 Non-neoplastic 18-46 6.25pCi ml 1 0.19 (0-2.2) (d2-15) An effect of cycle and (Meyer, 1977)
lesions oxygen 1 h 1.03 (0-6.3) (dl6-1) age. No effect of oral
contraceptives.
47 Mammoplasty or 2pCiml 1 (0.08-1.71) (follicular) An effect of cycle no (Masters
normal adjacent 4h (0.16-2.74) (luteal) effect of menstrual age. et al., 1977)
to benign lesions
90 Mammoplasty 16-51 - Proliferative phase d3-7 (Vogel et al.,
Mastectomy Luteal phase d15-20 1981)
(no mitosis)
83 Mammoplasty 15-40 - (0-1.35) (0-1.6) An effect of cycle. (Ferguson &
1 cm from Age not studied, Anderson
Fibroadenomas logarithmic transform 1981a)
116 Mammoplasty 15-45 - Extended series, effect (Anderson
1cm from fibro- of cycle and age, et al., 1982)
adenomas logarithmic transform
no effect of pill or parity.
An effect of laterality on
apoptosis.
75 Autopsy 15-56 dO-15 motoses/lubule An effect of cycle (Longacre &
material <24h dl6-20 (0-0.5) Bartow, 1986)
15 Normal tissue 2cm 21-55 2pCiml 0.74 (0.4-1.5) (21-32yrs) Ts-8.1 h: Age has an effect (Russo et al.,
from benign 1h 0.33 (0-1.5) (42-57yrs) topography important. 1987)
breast lesions Cycle not studied
113 Biopsy or 17-45 5YCiml 1 (0.04-5.7) Peak in cycle d26. (Going
mastectomy 2h 95%0 2 Declines with age.No effect et al., 1988)
material 4.5Atm of oral contraceptives,
logarithmic transform
122 Mammoplasty or 14-48 1 pCiml-' 2.65 (0-11.5) (0-0.6) (0-1.6) Age and cycle havean effect, Present
adjacent to 1 h Mean Mean square root transform. No study
fibroadenomas 0.16 0.34 effect of pill or parity.
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ing was absent in only one of101 samples. The 3HTdR
concentration and autoradiograph exposure times resulted in
very heavily labelled cells. There was little evidence that
labelled cells could not be detected throughout the sections.
The validity of the approach is also supported by the fact
that the MI and LI follow the same trends throughout. The
LI values are on average 17 times higher than the MI (LI/
MI = 16.6) which if we assume that the duration of mitosis is
1 h would suggest a duration of 17h for the S phase (Tj).
However, the length of S has been calculated to be 8.1 h
from double labelling studies (Russo et al., 1987) in which
case the labelling and mitotic data would suggest that the
duration of M in the breast is 30min.
Although we believe that a one hour incubation at 37°C in
a medium containing 3HTdR is a reliable means of obtain-
ing a flash labelling index there is some doubt as to whether
cells continue to enter S or M at a normal rate in the short
term cultures. Two previous studies (Flaxman & Lasfargues,
1973; Masters et al., 1977) employed a 4h labelling protocol
but there is little evidence that this results in an elevated LI
(TableII) compared with the flash labelling index which is
confirmed by preliminary short term continuous incubations
in 3HTdR in our laboratory. This throws some doubt on the
validity of double labelling or continuous labelling studies
(Russo et al., 1987). Some data suggest that mitosis and
particularly entry into mitosis is a sensitive process that is
disrupted by surgical procedures and short term culturing
(Potten, 1987). For this reason we believe that mitotic counts
should be conducted on tissue fixed rapidly after excision
and not on the material incubated in 3HTdR. In our studies
this was generally achieved within 10 minutes of surgery.
Assuming a Ts value of 8.1 h for intralobular epithelial
cells (Russo et al., 1987), and bearing in mind the preceding
comments, the LI data presented here could be taken to
indicate an upper limit for the turnover time of 308h for
human breast. However, the value of such a calculation is
questionable for a number of reasons: (a) this assumes that
all epithelial cells are involved in cell proliferation which is
unlikely. Russo et al., (1987) estimated, using continuous
labelling in vitro (see criticisms above), that the growth
fraction might be 0.32 in which case the cell cycle time could
be about 100 h; (b) it is questionable whether such a
calculation which assumes a steady state can be applied to a
system which is clearly cyclic in its proliferation (c) the value
of Ts must remain somewhat uncertain for this system (see
criticisms above); (d) little is known about the age distribu-
tion which influences this calculation. A rectangular distribu-
tion has been assumed but may not be valid.
There were no detectable changes through the menstrual
cycle in either the number of epithelial cells per terminal
duct cross section or the total number of epithelial cells per
lobule. This, together with the MI & Al values suggests that
the total proliferative activity in the breast during each
menstrual cycle is minimal - perhaps no more than one or
two cell divisions in each breast epithelial cell that is in the
growth fraction. The lack of change in the number of
epithelial cells may be because the apoptotic activity counter-
balances the mitotic activity. Certainly the apoptotic data
reflects the mitotic data very closely both in terms of the
general trends (Figures 4 & 5) and in terms of the absolute
values (Figures 4 & 5 and Table I). However, direct compar-
isons of the absolute values cannot be made because of
uncertainties in the relative durations of mitosis and apopto-
sis. It is possible that the breast has a very low growth
fraction and that at each cycle a few cells undergo several
rounds of cell division. More complex hierarchical models
are also possible with a very few stem cells which may divide
each cycle producing transitory daughters that divide a few
times before terminally differentiating. At each new cycle the
starting point may be from a few residual stem cells from the
preceding cycle or from a more complex mixture of stem and
dividing transit cells. However, in the absence of any firm
data such considerations must remain speculative.
The decline in LI with age is in agreement with the data of
Meyer (1977), Anderson et al., (1982) and Russo et al.
(1987). The LI declined with age in both halves of the
menstrual cycle and in women taking or not taking the
contraceptive pill. This age dependence of proliferation is
supported by experiments where human mammary epithe-
lium from woman of differing ages was grown in vitro where
fast and slow growing colonies were produced from both
young and old women but the fast colonies predominated in
the young women and slow growing ones in the older
women (Russo & Russo, 1982). All these data support the
concept that the elevated risk early in reproductive life may
be due to higher rates of cell proliferation during this period.
The reduced risk of breast cancer prouced by early preg-
nancy may be related to a change in the proliferative rates of
the breast after pregnancy; however, we could find no
significant differences in the LI between the 33 parous and
89 non-parous women after age and phase of the cycle had
been taken into account.
The LI was shown to vary in a cyclical manner. A
significantly higher LI was found in the second half of the
menstrual cycle which confirms the observations of Meyer
(1977) and Masters et al. (1977) on smaller groups of
patients.
The cyclical variation in LI was mirrored in the cyclical
variation of MI seen in this study and the studies of
Ferguson & Anderson (1981a), Anderson et al. (1982) and
Going et al. (1988). The estimated peak for MI was on the
25th day of the cycle in their study and on the 21st day in
this study. Vogel et al. (1981) examined the breasts of 90
patients which either had reduction mammoplasties or sub-
cutaneous mastectomies for 'benign' conditions. They found
mitoses predominently between days 3 and 7 which they
termed the proliferative phase. The reason why this study is
at variance with MI and the LI data from other studies is
not clear. It may be because of an unusual patient popula-
tion or a sampling error due to insufficient numbers of cells
counted. The majority of the literature suggests that the
maximum proliferation of mammary epithelium occurs
during the second half of the menstrual cycle. This finding is
at variance with the proposal that progesterone acts as an
antioestrogen with respect to the breast. Animal and in vitro
data are conflicting on this topic; in normal and malignant
mammary epithelium studied either in vitro or in vivo the use
of progestogens in addition to oestrogens either produces no
added effect, inhibition, or stimulation of cell growth
(Klevjer-Anderson & Buehring, 1980; Leung et al., 1981;
McManus & Welsche, 1984; Horwitz & Freidenberg, 1985;
Mauvais-Jarvis et al., 1986, Braunsberg et al., 1986; Hissom
& Moore, 1987; Longman and Beuhring, 1987).
The fact that progesterone can stimulate growth under
some experimental conditions may indicate that it is mitoge-
nic in vivo in women. Alternatively progesterone may prime
the cells to be responsive to growth promoting peptide
hormones since it has been shown to stimulate the synthesis
of lactogenic and epidermal growth factor receptors in
mammary tumour cell lines (Murphy et al., 1986a, b). A
recent report of increased incidence of breast cancer after
prolonged use of the high dose progesterone oral contracep-
tives may be important in this context (Pike et al., 1983).
However, in the present study and those of Meyer (1977)
and Anderson et al., (1982) there were no apparent differ-
ences in the proliferative indices between women taking oral
contraceptives and those not. In fact in the present study we
could detect no significant difference between the pill users
(n=33) and the non-pill users (n =89) for any parameter
measured after both age and stage of the menstrual cycle
were taken into account.
Epidemiological studies have shown recently that in
contradistinction to the 'oestrogen window' hypothesis of
Korenman (1980) the early occurrence of regular (and thus
probably ovular) menstrual cycles is associated with a
increased risk of breast cancer (Henderson et al., 1985, LaPROLIFERATION IN NORMAL HUMAN BREAST 169
Vecchia et al., 1985). Regular cycles are likely to be ovular
and thus progesterone would be expected to be secreted by
the corpus luteum. The association between progesterone
synthesis and risk is consistent with the finding in the study
reported here where the increased index is found in the same
phase of the cycle as maximum progesterone levels.
Studies on the factors that increase the risk of developing
breast cancer suggest that risk increases in situations where
the number of non-reproductive ovular menstrual cycles are
greatest, i.e. the more times the breast is subjected to the few
rounds of cell division that prepare the breast for the more
severe proliferative and differentiative changes required in
pregnancy, the greater is the risk of cancer. In contrast the
changes involved in pregnancy diminish the risk of breast
cancer if they occur early in life. The reduction in the total
number of menstrual cycles that would occur at each
pregnancy is not sufficient to account for this protection,
which is more likely to be due to some changes in the
proliferative/differentiative status of the breast. An early
pregnancy must in some way change the number, or suscep-
tibility, of carcinogenic target cells in the breast. However,
we could detect no differences in the parameters examined
between the parous and non-parous patients. One possibility
is that the breast of a parous woman contains a different
balance of stem and differentiated transitory proliferative
cells. It is possible that with successive menstrual cycles after
parity the changes in the breast preparative to further
pregnancies are adequately accommodated by a greater
proliferative contribution from differentiated cells rather
than stem cells and the latter may play a much greater role
in carcinogenesis.
Whether or not any of the indices measured here might
prove to be predictive for the patients (approximately 10)
expected to develop cancer remains to be seen. Although a
general abnormally high proliferative activity throughout the
breast may predispose the tissue to malignant transformation
cancers may originate from one or a few isolated cells with
abnormal proliferative/differentiative behaviour within a
pool of cells behaving normally. One point that remains
unclear is whether or not a patient with a high LI value after
age and stage of cycle have been taken into account, has a
generally elevated proliferative activity or has merely been
sampled by chance at the time of peak proliferative activity
for that menstrual cycle. In other words, it is unclear
whether the proliferative changes through the cycle for an
individual are best described by a broad peak in the later
part of the cycle or by a sharp discrete peak, or step up, in
proliferative activity. The variability observed here and in
the other studies then may be the consequence of either
differences in absolute levels of proliferation between
patients or it may be the consequence of a wide range of
differences in the timing of the discrete peaks in proliferative
activity between patients which may reflect differences
between patients in the timing of their hormonal stimuli, i.e.
patients may differ in the total amount of proliferation that
occurs each cycle or they may all have about the same
amount of proliferation but differ in the time in the cycle
when they undertake this proliferation.
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